Japanese society of hypertension (JSH) guidelines for self-monitoring of blood pressure at home
…, H Hayashi, O Tochikubo, M Miyakawa… - Hypertension …, 2003 - jstage.jst.go.jp
Home blood pressure (BP) measurements are indispensable for the improvement of hypertension
management in medical practice as well as for the recognition of hypertension in the …
management in medical practice as well as for the recognition of hypertension in the …
[HTML][HTML] The Japanese Society of Hypertension guidelines for self-monitoring of blood pressure at home
…, T Ohkubo, I Kuwajima, M Miyakawa - Hypertension …, 2012 - nature.com
Yutaka Imai1, Kazuomi Kario2, Kazuyuki Shimada3, Yuhei Kawano4, Naoyuki Hasebe5,
Hideo Matsuura6, Takuya Tsuchihashi7, Takayoshi Ohkubo8, Iwao Kuwajima9 and Masaaki …
Hideo Matsuura6, Takuya Tsuchihashi7, Takayoshi Ohkubo8, Iwao Kuwajima9 and Masaaki …
Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes
…, T Furuki, H Kobori, M Miyakawa… - Journal of …, 2017 - journals.sagepub.com
We conducted a descriptive case study to examine the effects of sodium-glucose cotransporter
2 (SGLT2) inhibitors on urinary angiotensinogen excretion, which represents the function …
2 (SGLT2) inhibitors on urinary angiotensinogen excretion, which represents the function …
[HTML][HTML] Factors influencing changes in hemoglobin A1c and body weight during treatment of type 2 diabetes with ipragliflozin: interim analysis of the ASSIGN-K study
…, N Sasai, H Kaneshige, M Miyakawa… - Journal of clinical …, 2016 - ncbi.nlm.nih.gov
Background Ipragliflozin is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor that
blocks glucose reabsorption in the proximal tubules. SGLT2 inhibitors are expected to be …
blocks glucose reabsorption in the proximal tubules. SGLT2 inhibitors are expected to be …
[HTML][HTML] Sustained neutralizing antibodies 6 months following infection in 376 Japanese COVID-19 survivors
A Goto, H Go, K Miyakawa, Y Yamaoka… - Frontiers in …, 2021 - frontiersin.org
Objective: There is scarce evidence regarding the long-term persistence of neutralizing
antibodies among coronavirus disease 2019 (COVID-19) survivors. This study determined …
antibodies among coronavirus disease 2019 (COVID-19) survivors. This study determined …
[HTML][HTML] Practice and awareness of physicians regarding home blood pressure measurement in Japan
…, R Inoue, M Kikuya, N Mano, M Miyakawa… - Hypertension …, 2010 - nature.com
The Japanese Society of Hypertension published guidelines for home blood pressure (HBP)
measurement in 2003 and for the management of hypertension in 2004. The objective of …
measurement in 2003 and for the management of hypertension in 2004. The objective of …
Canagliflozin increases calorie intake in type 2 diabetes without changing the energy ratio of the three macronutrients: CANA-K study
…, Y Matsuzawa, S Ito, M Miyakawa… - Diabetes technology …, 2020 - liebertpub.com
Background: Sodium/glucose cotransporter-2 (SGLT2) inhibitors improve glycemic control
and reduce body weight by increasing glycosuria. Although a compensatory increase of food …
and reduce body weight by increasing glycosuria. Although a compensatory increase of food …
Pretreatment body mass index affects achievement of target blood pressure with sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus and …
…, A Mokubo, M Takihata, K Sato, M Miyakawa… - Hypertension …, 2024 - nature.com
Sodium-glucose cotransporter 2 inhibitor (SGLT2-I) shows excellent antihypertensive effects
in addition to its hypoglycemic effects. However, whether body mass index (BMI) affects the …
in addition to its hypoglycemic effects. However, whether body mass index (BMI) affects the …
[HTML][HTML] Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes: interim outcome of the ASSIGN-K study
…, T Saito, K Shinoda, M Miyakawa… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Background Ipragliflozin is a sodium-glucose co-transporter 2 inhibitor that can improve
glycemic control and reduce body weight and blood pressure in patients with type 2 diabetes …
glycemic control and reduce body weight and blood pressure in patients with type 2 diabetes …
Cross-sectional survey of hypertension management in clinical practice in Japan: the Kanagawa Hypertension Study 2021 conducted in collaboration with Japan …
…, N Hatori, T Furuki, H Sakai, M Miyakawa… - Hypertension …, 2023 - nature.com
We aim to assess the data of patients with hypertension in Kanagawa Prefecture, Japan,
collected in 2021 that were provided by the Japan Medical Association Database of Clinical …
collected in 2021 that were provided by the Japan Medical Association Database of Clinical …